## UNITED STATES

## SECURITIES AND EXCHANGE COMMISSION

# WASHINGTON, DC 20549

## FORM 8-K

# CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

Date of report (Date of earliest event reported): November 12, 2015

<u>Repros Therapeutics Inc.</u>
(Exact Name of Registrant as Specified in Charter)

	(Exact Name of Registrant as Specified in Charter)	
<u>Delaware</u> (State or Other Jurisdiction of Incorporation)	001-15281 (Commission File Number)	76-0233274 (I.R.S. Employer Identification No.)
	ch Place, Suite B-7 odlands, TX	77380
(Address of Principal Executive Offices)		(Zip Code)
Regi	strant's telephone number, including area code: (281) 71	9-3400
Check the appropriate box below if the Form 8-K provisions (see General Instruction A.2. below):	filing is intended to simultaneously satisfy the filing obli	ligation of the registrant under any of the following
☐ Soliciting material pursuant to Rule 14a-12☐ Pre-commencement communications pursu	425 under the Securities Act (17 CFR 230.425). 2 under the Exchange Act (17 CFR 240.14a-12). ant to Rule 14d-2(b) under the Exchange Act (17 CFR 24 ant to Rule 13e-4(c) under the Exchange Act (17 CFR 24	\ //

# Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On November 12, 2015, Michael Suesserman resigned from the Board of Directors of Repros Therapeutics Inc. (the "Company"). Mr. Suesserman informed the Company that his resignation was due solely to a change in his employment circumstances, and not due to any matter relating to the Company's operations, policies or practices.

# **SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

## REPROS THERAPEUTICS INC.

By: /s/ Katherine Anderson

Katherine Anderson

CFO

Dated: November 16, 2015